Straumann Holding Ag · SIX:STMN
Straumann — EuroPerio 2006
50 slides from Straumann's conference presentation, Jun 30, 2006
Slide 1: Straumann 2006: Combining solutions in implant dentistry and oral tissue regeneration
Straumann 2006 Combining solutions in implant dentistry and oral tissue regeneration EuroPerio 2006 Madrid 30 June 06
Slide 2: Disclaimer
Disclaimer This presentation contains certain “forward-looking statements”, which can be identified by use of terminology such as “expect”, “expectation”, “intend”, “continue”, “achieve”, “maintain”, “improve”, “foresee”, “anticipate”, “product introductions”, “outlook”, “forecast”, or similar wordi
Slide 3: Table of contents
Table of contents 1. Our unique position in a dynamic industry 2. Straumann Dental Implant System – offering a new standard of patient care 3. Straumann Regenerative System – enhancing treatment options 4. Q&A STRAUMANN June 2006 3
Slide 4: Our unique position in a dynamic industry
Our unique position in a dynamic industry Dr Sandro Matter Executive Vice President Products Division
Slide 5: Straumann in brief
Straumann in brief • A world leader in implant dentistry and oral tissue regeneration • #2 globally, #1 in Europe and Asia, #2 in North America • Founded in 1954 • 1420 employees • HQ in Basel; production in Villeret (CH), Malmö (S), and Andover (USA) • B2B model serving customers in 60 countries th
Slide 6: Straumann's focused range of products
Straumann’s focused range of products STRAUMANN June 2006 6
Slide 7: A unique partnership with the ITI network
A unique partnership with the ITI network • A fast-growing independent academic organization that unites professionals around the world in a dynamic network of proficient and collegial exchange in the fields of research and clinical practice. • 440 Fellows, 1175 Members,15 country sections • 23 rese
Slide 8: Global ITI outreach in 2006
Global ITI outreach in 2006 • 21 national scientific congresses and events • 1st Asian regional congress • World Symposium in New York in 2007 STRAUMANN June 2006 8
Slide 9: Market trends
straumann AN Market trends COMMITTED TO SIMPLY DOING MORE FOR DENTAL PROFESSIONALS
Slide 10: Drivers for implant dentistry
Drivers for implant dentistry Demographics • Aging population and increasing • Increasing wealth (implant treatment not reimbursed*) wealth • Awareness of benefits of implants over conventional Growing patient solutions awareness • Increasing importance of esthetics Increasing • Long-term clinical s
Slide 11: Trends in implant dentistry
Trends in implant dentistry Increasing • Easy handling of system importance of • Documented long-term safety and clinical benefit general dentists • Access to training and support • Reduction of treatment sessions and costs Faster • Accelerated osseointegration and bone augmentation “time-to-teeth”
Slide 12: Table of contents
Table of contents 1. Our unique position in a dynamic industry 2. Straumann Dental Implant System – offering a new standard of patient care 3. Straumann Regenerative System – enhancing treatment options 4. Q&A STRAUMANN June 2006 12
Slide 13: Straumann Dental Implant System – offering a new standard of patient care
Straumann Dental Implant System – offering a new standard of patient care
Slide 14: The proven concept
The proven concept • One system – one concept Simple • Logical component structure • Procedures that are easy to learn • Successful outcomes with any indication Versatile • Flexible choice of surgical procedure • Wide range of prosthetic options • Implants designed for optimal tissue response • Mors
Slide 15: Straumann leads surface innovation
Straumann leads surface innovation 1974 1994 2005 1st generation 2nd generation 3rd generation TPS SLA SLActive SLActive Macro Micro&Macro Molecular Development of Development of surface surface topography chemistry STRAUMANN June 2006 15
Slide 16: SLActive – Summary of clinical benefits
SLActive – Summary of clinical benefits Faster osseointegration for higher security in every indication Reduced healing times from 6-8 weeks to 3-4 weeks Increased treatment predictability in critical treatment protocols STRAUMANN June 2006 16
Slide 17: SLActive – Science proven in patients
SLActive – Science proven in patients ‘Osstell’ study • 2 clinics (US and CH), 31 patients, 62 implants • SLActive reduces the stability dip • Higher stability after 2-4 weeks: 2x faster than ‘gold standard’ Multicenter study • 20 clinics in 9 countries • 300 patients, > 400 implants • Immediate and
Slide 18: Histological analysis of early peri-implant tissue reactions to SLActive and SLA
Histological and immunohistochemical analysis of very early peri-implant tissue reactions to SLActive and SLA implants A preclinical pilot study Schwarz F et al.: Clinical Oral Implants Research* *Peer reviewed; accepted for publication STRAUMANN June 2006 18
Slide 19: SLActive – Immediate onset of healing
SLActive – Immediate onset of healing SLA® SLActive Day 1 Day 1 Stabilized blood clot Collapsed blood clots STRAUMANN June 2006 19
Slide 20: SLActive – Bone forming 4 days after placement
SLActive – Bone forming 4 days after placement SLA® SLActive Day 4 Day 4 STRAUMANN June 2006 20
Slide 21: SLActive – Mineralized and organized bone at 1 week
SLActive – Mineralized and organized bone at 1 week SLA® SLActive Day 7 Day 7 Mineralized, organized Not yet structured STRAUMANN June 2006 21
Slide 22: SLActive – Significantly more bone at 2 weeks
SLActive – Significantly more bone at 2 weeks SLA® SLActive Day 14 Day 14 Old bone New bone New bone STRAUMANN June 2006 22
Slide 23: Results
Results SLActive vs. SLA • Significantly increased proliferation of vascular structures • Significantly increased osteocalcin activity & earlier bone formation • Significant qualitative differences in bone formation (histology) STRAUMANN June 2006 23
Slide 24: SLActive – International recognition
SLActive – International recognition STRAUMANN June 2006 24
Slide 25: Table of contents
Table of contents 1. Our unique position in a dynamic industry 2. Straumann Dental Implant System – offering a new standard of patient care 3. Straumann Regenerative System – enhancing treatment options 4. Q&A STRAUMANN June 2006 25
Slide 26: Straumann Regenerative System – enhancing treatment options
Straumann Regenerative System – enhancing treatment options Anja Mett Vice President Business Unit, Regenerative Products
Slide 27: Solutions in implantology and tissue regeneration
Solutions in implantology and tissue regeneration Straumann Regenerative System Bone regeneration Periodontal regeneration Bone Block Fixation Straumann Straumann Emdogain Straumann Dental Implant PLUS BoneCeramic Emdogain System STRAUMANN June 2006 27
Slide 28: Periodontal disease: a major cause of tooth loss
Periodontal disease: a major cause of tooth loss Course of disease • >60% of adults affected Plaque + calculus Æ inflammation Æ pocket formation Æ attachment destroyed Æ tooth loss • 5-20% of adults have severe disease • Main cause of tooth loss • Only 60% of patients are treated Tooth - 1 in 10 tre
Slide 29: Repair or regenerate?
Repair or regenerate? Repair Regeneration • Does not fully restore biological • True functional attachment re- structure or function established • Epithelial growth down to the • Cementum, periodontal ligament, preoperative level alveolar bone • Unpredictable long-term results • Predictable long-ter
Slide 30: Straumann Emdogain – An established standard in periodontal tissue regeneration
Straumann® Emdogain – An established standard in periodontal tissue regeneration • Protein-based technology, (Enamel Matrix Derivative) • Promotes predictable re-growth of hard and soft tissues leading to regeneration of tooth attachment • Enhanced wound healing, increased patient comfort • Easy-to-
Slide 31: Straumann Emdogain – How it works
Straumann® Emdogain – How it works VIDEO STRAUMANN June 2006 31
Slide 32: True regeneration in a wide range of indications
True regeneration in a wide range of indications Regeneration of a true functional attachment with • cementum • periodontal ligament 3-Wall Defect 2-Wall Defect 1-Wall Defect • alveolar bone Furcation Recession Wide Intrabony Defect STRAUMANN June 2006 32
Slide 33: Straumann Emdogain in intrabony defects
Straumann® Emdogain in intrabony defects First visit 2 years after treatment Acknowledgment to Dr David Nisand, Paris STRAUMANN June 2006 33
Slide 34: Straumann Emdogain – Unparalleled clinical evidence
Straumann® Emdogain – Unparalleled clinical evidence • >140 scientific publications • > 40 published clinical studies demonstrating efficacy • >1500 defects in over 1200 patients documented • 60-70% defect fill measured 1 year post treatment True regeneration • Significant gain in clinical attachmen
Slide 35: Latest clinical findings confirm long-term success
Latest clinical findings confirm long-term success Rasperini et al (Int J Periodontics Restorative Dent, 2005) • Series of cases with advanced infrabony defects • Significant periodontal attachment level gain, probing reduction and bone fill • All clinical parameters stable after 5-7 years Heden et
Slide 36: Solutions in implantology and tissue regeneration
Solutions in implantology and tissue regeneration Straumann Regenerative System Bone regeneration Periodontal regeneration Bone Block Fixation Straumann Straumann Emdogain Straumann Dental Implant PLUS BoneCeramic Emdogain System STRAUMANN June 2006 36
Slide 37: 25% of all dental implant procedures require some form of bone augmentation
25% of all dental implant procedures require some form of bone augmentation • Bony defects of the alveolar ridge • Sinus floor elevations • Tooth extraction sites • Peri-implant defects • Periodontal intrabony defects STRAUMANN June 2006 37
Slide 38: Straumann BoneCeramic
Straumann® BoneCeramic • Fully synthetic bone substitute with optimized morphology leading the way to new vital bone • Bi-phasic calcium phosphate: • β-TCP initiates mineralization • HA protects from excessive resorption • Chemically synthesized (homogeneous distribution, consistent quality) • Excel
Slide 39: Optimized morphology
Optimized morphology Favours vascularisation, osteoblast migration and bone deposition < 1000 µm • Homogeneous granule size • >90% total porosity • Optimized topography for osteocontuctive properties • Interconneted pores < 100 – 500 µm 200µm STRAUMANN June 2006 39
Slide 40: Histological results after 6 months
Histological results after 6 months * Pre- treatment * * BoneCeramic* integrated in new bone (red stain) Bone height maintained Ongoing bone formation (purple stain) at 15 months Courtesy of Bern University STRAUMANN June 2006 40
Slide 41: Ongoing scientific program with Straumann BoneCeramic
Ongoing scientific program with Straumann® BoneCeramic Existing scientific evidence on bi-phasic calcium phosphates: Significantly more bone formation than with hydroxyapatite alone Bone regeneration and successful dental implant placement in augmented sites Extensive clinical program underway
Slide 42: Solutions in implantology and tissue regeneration
Solutions in implantology and tissue regeneration Straumann Regenerative System Bone regeneration Periodontal regeneration Bone Block Fixation Straumann Straumann Emdogain Straumann Dental Implant PLUS BoneCeramic Emdogain System STRAUMANN June 2006 42
Slide 43: Introducing Straumann Emdogain PLUS
Introducing Straumann® Emdogain PLUS NEW STRAUMANN June 2006 43
Slide 44: Straumann Emdogain PLUS
Straumann® Emdogain PLUS Straumann® Emdogain 0.7 ml • for periodontal regeneration PLUS Straumann® BoneCeramic 400-700 µm • for filling and tissue support for wide intrabony defects, furcations and extraction sites STRAUMANN June 2006 44
Slide 45: Expanding the regenerative options
Expanding the regenerative options W NE Recession 3-Wall 2-Wall 1-Wall Furcation Wide intrabony defect, Extraction site Straumann® Emdogain XX XX X X X Straumann® Emdogain PLUS XX XX XX STRAUMANN June 2006 45
Slide 46: Straumann Emdogain PLUS to support soft tissue in wide intrabony defects
Straumann® Emdogain PLUS to support soft tissue in wide intrabony defects Courtesy of Prof. Anton Sculean, Netherlands STRAUMANN June 2006 46
Slide 47: Straumann Emdogain PLUS – Bringing regeneration to patients
Straumann® Emdogain PLUS – Bringing regeneration to patients • Europe: Launch at EuroPerio • USA: H1 2007, pending approvals • Asia: Roll-out in initial markets as of Q4 2006 Promoting regeneration and tissue stability STRAUMANN June 2006 47
Slide 48: Straumann Emdogain PLUS – Scientific evidence
Straumann® Emdogain PLUS – Scientific evidence Latest clinical findings will be presented at the Straumann Corporate Forum during EuroPerio: 30 June 2006 14.30-16.30h Room N106 STRAUMANN June 2006 48
Slide 49: Outlook Products
Outlook Products • Straumann will continue to optimize its range of products and services with meaningful innovations. • We shall also remain true to our philosophy of introducing products that offer both clear benefits to customers and clinical advantages. • We shall continue adapting the product r
Slide 50: Questions & Answers
straumann AN Questions & Answers COMMITTED TO SIMPLY DOING MORE FOR DENTAL PROFESSIONALS